MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Amgen Inc. $AMGN

by · The Cerbat Gem

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 8.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 480,458 shares of the medical research company’s stock after buying an additional 36,551 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.09% of Amgen worth $149,667,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of AMGN. Wealth Preservation Advisors LLC purchased a new stake in shares of Amgen during the 1st quarter worth $25,000. Pinney & Scofield Inc. purchased a new stake in shares of Amgen during the 4th quarter worth $26,000. First Pacific Financial lifted its position in shares of Amgen by 304.5% during the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock worth $28,000 after purchasing an additional 67 shares during the last quarter. Activest Wealth Management lifted its position in shares of Amgen by 3,433.3% during the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock worth $33,000 after purchasing an additional 103 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in Amgen during the 4th quarter worth $36,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.76% of the stock is owned by company insiders.

Analyst Ratings Changes

AMGN has been the topic of several research analyst reports. Morgan Stanley lifted their price target on shares of Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Citigroup lifted their price target on shares of Amgen from $305.00 to $310.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Guggenheim initiated coverage on shares of Amgen in a research note on Tuesday, May 20th. They set a “neutral” rating and a $288.00 price target on the stock. Piper Sandler lifted their price target on shares of Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a research note on Monday, August 25th. Finally, Raymond James Financial initiated coverage on shares of Amgen in a research note on Wednesday. They set a “market perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $304.43.

Get Our Latest Report on AMGN

Amgen Trading Down 1.3%

Shares of Amgen stock opened at $280.10 on Friday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $339.17. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The company’s 50-day simple moving average is $293.72 and its 200-day simple moving average is $292.67. The firm has a market cap of $150.79 billion, a price-to-earnings ratio of 22.90, a price-to-earnings-growth ratio of 2.47 and a beta of 0.49.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.4%. Amgen’s payout ratio is currently 77.84%.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Further Reading